When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.

J. Michael Gaziano, MD, MPH, an internationally recognized chronic disease epidemiologist, will deliver the 15th annual Grant R. Wilkinson Distinguished Lectureship in Clinical Pharmacology on Thursday, April 11.

Speakers at the inaugural SCRIPS Spring Symposium (Supporting Careers in Research for Interventional Physicians and Surgeons) last week were, from left, Kelle Moley, MD, senior vice president and chief scientific officer of the March of Dimes; 2018 SCRIPS Scholars Yash Choksi, MD, and Akshitkumar Mistry, MD; and Anil Rustgi, MD.

A medicine currently being tested as a chemoprevention agent for multiple types of cancer has more than one trick in its bag when it comes to preventing stomach cancer, Vanderbilt researchers have discovered.

The Terry Burke Fund for Bladder Cancer Research at Vanderbilt-Ingram Cancer Center is supporting a range of discovery research aimed at improving outcomes for bladder cancer patients, and it is helping train the next generation of bladder cancer physician-scientists.

Using gene transfer technologies to reprogram adult human kidney cells could lead to novel therapies for chronic kidney disease.

Vanderbilt-Ingram Cancer Center Ambassadors surpassed the $1 million mark with the awarding of the group’s latest research grants.